Free radicals, cytokines, and respiratory muscles in COPD patients

Clinical Pulmonary Medicine

Volumn 14, Issue 3, 2007, Pages 117-126

  Gea, Joaquim ^a,b   Barreiro, Esther ^a   Orozco Levi, Mauricio ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Inflammation; Muscle dysfunction; Muscle remodeling; Oxidative stress; Respiratory diseases

Indexed keywords

CYTOKINE; FREE RADICAL;

BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAPHRAGM DISEASE; HUMAN; INFLAMMATORY CELL; MUSCLE DISEASE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PNEUMONIA; REVIEW; SKELETAL MUSCLE;

EID: 34248549118     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e3180575dcd     Document Type: Review

References (77)

1. DiMarco A, Romaniuk JR, Supinski GS. Paraesternal and external intercostal responses to various respiratory manoeuvres. J Appl Physiol. 1992;73:979-986.
2. Barreiro E, Gea J, Mattar G, et al. Expression and carbonylation of creatine kinase in the quadriceps femoris muscle of COPD patients. Am J Respir Cell Mol Biol. 2005;33:636-642.
3. De Troyer A, Loring SH. Actions of the respiratory muscles. In: Roussos Ch, ed. The Thorax, Part A: Physiology. New York: Marcel Dekker; 1995:535-563.
4. De Troyer A, Pride NB. The chest wall and respiratory muscles in chronic obstructive pulmonary disease. In: Roussos Ch, ed. The Thorax, Part C: Disease. New York: Marcel Dekker; 1995:1975-2006.
5. American Thoracic Society and European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(suppl):S1-S40.
6. Similowski T, Yan S, Gauthier AP, et al. Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med. 1991; 325:917-923.
7. Levine S, Kaiser L, Leferovich J, et al. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med. 1997;337:1799-1806.
8. Orozco-Levi M, Gea J, Lloreta J, et al. Subcellular adaptation of the human diaphragm in chronic obstructive pulmonary disease. Eur Respir J. 1999;13:371-378.
9. Levine S, Nguyen T, Kaiser LR, et al. Human diaphragm remodelling associated with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168:705-713.
10. Ramírez-Sarmiento A, Orozco-Levi M, Barreiro E, et al. Expiratory muscle endurance in chronic obstructive pulmonary disease. Thorax. 2002;57:132-136.
11. Gea J, Orozco-Levi M, Barreiro E, et al. Structural and functional changes in the skeletal muscles of COPD patients: the "Compartments" theory. Monaldi Arch Chest Dis. 2001;56:214-224.
12. Reid MB, Haack KE, Franchek KM, et al. Reactive oxygen in skeletal muscle. I. Intracellular oxidant kinetics and fatigue in vitro. J Appl Physiol. 1992;73:1797-1804.
13. Davies KJ, Quintanilha AT, Brooks GA, et al. Free radicals and tissue damage produced by exercise. Biochem Biophys Res Commun. 1982; 107:1198-1205.
14. Supinski G. Free radical induced respiratory muscle dysfunction. Mol Cell Biochem. 1998;179:99-110.
15. Parks DA, Granger DN. Ischemia-induced vascular changes: role of xanthine oxidase and hydroxyl radicals. Am J Physiol. 1983;245:G285-G289.
16. Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev. 2001;81:209-237.
17. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol. 1996;271:C1424-C1437.
18. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol. 1996;9:836-844.
19. Tamir S, Burney S, Tannenbaum SR. DNA damage by nitric oxide. Chem Res Toxicol. 1996;9:821-827.
20. Eiserich JP, Estevez AG, Bamberg TV, et al. Microtubule dysfunction by posttranslational nitrotyrosination of alpha-tubulin: a nitric oxidedependent mechanism of cellular injury. Proc Natl Acad Sci USA. 1999;96:6365-6370.
21. MacKnee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2: 50-60.
22. Rahman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell Biochem Biophys. 2005;43:167-188.
23. Langen RC, Korn SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med. 2003;35:226-235.
24. Barreiro E, Gea J, Corominas JM, et al. Nitric oxide synthases and protein oxidation in the quadriceps femoris of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2003;29: 771-778.
25. Koechlin C, Maltais F, Saey D, et al. Hypoxemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease. Thorax. 2005;60:834-841.
26. Gosker HR, Bast A, Haenen GR, et al. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. Respir Med. 2005; 99:118-125.
27. Barreiro E. Gáldiz JB, Mariñán M, et al. Respiratory loading intensity and diaphragm oxidative stress: N-acetylcysteine effects. J Appl Physiol. 2006;100:555-563.
28. Hayot M, Barreiro E, Perez A, et al. Morphological and functional recover from diaphragm injury: an in vivo rat diaphragm injury model. J Appl Physiol. 2001;90:2269-2278.
29. Barreiro E, De la Puente B, Minguella J, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:1116-1124.
30. Allaire J, Maltais F, Doyon JF, et al. Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. Thorax. 2004;59:673-678.
31. Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc. 1998;30:1467-1474.
32. Couillard A, Maltais F, Saey D, et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1664-1669.
33. Barriero E, Sanchez D, Gladiz JB, et al. N-acetylcysteine increases manganese superoxide dismutase activity in septic rat diaphragms. Eur Respir J. 2005;26:1032-1039.
34. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report. Bethesda: National Heart, Lung and Blood Institute. Update of the Management Sections. Available at: http://www.goldcopd.com. Accessed August 10, 2005.
35. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580.
36. Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;150:1453-1455.
37. Schols AM, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819-824.
38. Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax. 2001;56:432-437.
39. Sauleda J, Garcia-Palmer FJ, Gonzalez G, et al. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis. Am J Respir Crit Care Med. 2000;161:32-35.
40. De Jong JW, Van der Belt-Gritter B, Koeter GH, et al. Peripheral blood lymphocyte cell subsets in subjects with chronic obstructive pulmonary disease: association with smoking, IgE and lung function. Respir Med. 1997;91:67-76.
41. Salvi S, Blomberg A, Rudell B, et al. Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. Am J Respir Crit Care Med. 1999;159:702-709.
42. Van Eeden SF, Tan WC, Suwa T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med. 2001;164: 826-830.
43. Nordskog BK, Fields WR, Hellmann GM. Kinetic analysis of cytokine response to cigarette smoke condensate by human endothelial and monocytic cells. Toxicology. 2005;212:87-97.
44. Zhang J, Liu Y, Shi J, et al. Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. Exp Biol Med. 2002;227:823-829.
45. Zhu E, Petrof BJ, Gea J, et al. Diaphragm muscle fiber injury after inspiratory resistive breathing. Am J Respir Crit Care Med. 1997;155: 1110-1116.
46. Orozco-Levi M, Lloreta J, Minguella J, et al. Injury of the human diaphragm associated with exertion and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1734-1739.
47. Mayer A, Ramírez-Sarmiento A, Nascimento O, et al. Acute and severe injury of respiratory and peripheral muscles associated with short-term exposure to tobacco smoking. Eur Respir J. 2004;24(suppl 8):150s.
48. Tidball JG. Inflammatory cell response to acute muscle injury. Med Sci Sports Exerc. 1995;27:1022-1032.
49. Cantini M, Carraro U. Macrophage-released factor stimulates selectively myogenic cells in primary muscle culture. J Neuropathol Exp Neurol. 1995;54:121-128.
50. Chen SE, Gerken E, Zhang Y, et al. Role of TNF-alpha signaling in regeneration of cardiotoxin-injured muscle. Am J Physiol Cell Physiol. 2005;289:C1179-C1187.
51. Hoshino E, Pichard C, Greenwood CE, et al. Body composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Physiol. 1991;260:E27-E36.
52. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med. 2002;166:479-484.
53. Li YP, Reid MB. Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol. 2001;13:483- 487.
54. Li YP, Schwartz RJ, Waddell ID, et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 1998;12:871-880.
55. Langen RC, Schols AM, Kelders MC, et al. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J. 2001;15:1169-1180.
56. Li X, Moody MR, Engel D, et al. Cardiacspecific overexpression of tumor necrosis factor-a causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation. 2000;102:1690-1696.
57. Langen RC, Schols AM, Kelders MC, et al. Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol. 2002;283:C714-C721.
58. Pan S, An P, Zhang R, et al. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol. 2002;22:7512-7523.
59. Gehr G, Gentz R, Brockhaus M, et al. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J Immunol. 1992;149:911-917.
60. Saghizadeh M, Ong JM, Garvey WT, et al. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996;97:1111-1116.
61. De Rossi M, Bernasconi P, Baggi F, et al. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol. 2000;12:1329-1335.
62. Collins RA, Grounds MD. The role of tumor necrosis factor-alpha (TNF-alpha) in skeletal muscle regeneration. Studies in TNF-alpha(-/-) and TNF-alpha(-/-)/LT-alpha(-/-) mice. J Histochem Cytochem. 2001;49:989-1001.
63. Warren GL, Hulderman T, Jensen N, et al. Physiological role of tumor necrosis factor alpha in traumatic muscle injury. FASEB J. 2002;16:1630-1632.
64. Zador E, Mendler L, Takacs V, et al. Regenerating soleus and extensor digitorum longus muscles of the rat show elevated levels of TNF-alpha and its receptors, TNFR-60 and TNFR-80. Muscle Nerve. 2001;24:1058-1067.
65. Frost RA, Lang CH. Skeletal muscle cytokines: regulation by pathogenassociated molecules and catabolic hormones. Curr Opin Clin Nutr Metab Care. 2005;8:255-263.
66. Musaro A, McCullagh K, Paul A, et al. Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195-200.
67. Cabane C, Englaro W, Yeow K, et al. Regulation of C2C12 myogenic terminal differentiation by MKK3/p38alpha pathway. Am J Physiol Cell Physiol. 2003;284:C658-C666.
68. Kaliman P, Canicio J, Testar X, et al. Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-kappaB and inducible nitric-oxide synthase define a common myogenic signaling pathway. J Biol Chem. 1999;274:17437-17444.
69. Kuru S, Inukai A, Kato T, et al. Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (Berl). 2003;105:217-224.
70. Coronell C, Ramirez A, Martinez-Llorens JM, et al. Functional relevance of peripheral muscle injury in patients with COPD. Proc Am Thor Soc. 2006;3:A26.
71. Casadevall C, Coronell C, Ramirez-Sarmiento A, et al. Upregulation of proinflammatory cytokine genes in the external intercostal muscle of COPD patients. Eur Respir J. In press.
72. Vassilakopoulos T, Divangahi M, Rallis G, et al. Differential cytokine gene expression in the diaphragm in response to strenuous resistive breathing. Am J Respir Crit Care Med. 2004;170:154-161.
73. Argiles JM, López-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev. 1999;19:223-248.
74. Lang CH, Fan J, Cooney R, Vary TC. IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol. 1996;270:E430-E437.
75. Ji SQ, Neustrom S, Willis GM, et al. Proinflammatory cytokines regulate myogenic cell proliferation and fusion but have no impact on myotube protein metabolism or stress protein expression. Interferon Cytokine Res. 1998;8:879-888.
76. Haddad F, Zaldivar F, Cooper DM, et al. IL-6-induced skeletal muscle atrophy. J Appl Physiol. 2005;98:911-917.
77. Tsujinaka T, Fujita J, Ebisui C, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest. 1996;97:244-249.